YU67692A - Postupak za dobijanje novih smeša na bazi derivata iz klase taksana - Google Patents

Postupak za dobijanje novih smeša na bazi derivata iz klase taksana

Info

Publication number
YU67692A
YU67692A YU67692A YU67692A YU67692A YU 67692 A YU67692 A YU 67692A YU 67692 A YU67692 A YU 67692A YU 67692 A YU67692 A YU 67692A YU 67692 A YU67692 A YU 67692A
Authority
YU
Yugoslavia
Prior art keywords
mixtures based
procedure
ethanol
new mixtures
obtaining new
Prior art date
Application number
YU67692A
Other languages
English (en)
Other versions
YU48913B (sh
Inventor
J.P. Bastart
T. Dupechez
J.L. Fabre
Original Assignee
Rhone-Poulenc Rorer S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9414814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU67692(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone-Poulenc Rorer S.A. filed Critical Rhone-Poulenc Rorer S.A.
Publication of YU67692A publication Critical patent/YU67692A/sh
Publication of YU48913B publication Critical patent/YU48913B/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Paints Or Removers (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)

Abstract

ovaj pronalazak se odnosi na postupak za dobivanje novih smeša na bazi derivata iz klase taksana, formule (I) u kojoj R označava atom vodonika ili radikal acetil, simbol R1 označava radikal terc-butoksikarbonilamino ili benzoilamino u rastvoru u površinski aktivnom agensu koji je odabran izmedju polisorbata, polioksietilenglikola i hidrogenizovanih ricinusovih ulja skoro bez etanola. Postupak se sastoji u tome da se aktivna materija rastvori u etanolu, doda površinski aktivni agens i upari etanol.
YU67692A 1991-07-08 1992-07-06 Postupak za dobijanje novih smeša na bazi derivata iz klase taksana YU48913B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9108527A FR2678833B1 (fr) 1991-07-08 1991-07-08 Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.

Publications (2)

Publication Number Publication Date
YU67692A true YU67692A (sh) 1995-12-04
YU48913B YU48913B (sh) 2002-11-15

Family

ID=9414814

Family Applications (1)

Application Number Title Priority Date Filing Date
YU67692A YU48913B (sh) 1991-07-08 1992-07-06 Postupak za dobijanje novih smeša na bazi derivata iz klase taksana

Country Status (28)

Country Link
US (1) US5403858A (sh)
EP (4) EP0522936A1 (sh)
JP (2) JP2595458B2 (sh)
KR (1) KR0136722B1 (sh)
AT (2) ATE161193T1 (sh)
CA (2) CA2102778C (sh)
CZ (1) CZ280965B6 (sh)
DE (3) DE69217056D1 (sh)
DK (2) DK0593656T5 (sh)
ES (2) ES2096091T7 (sh)
FI (2) FI111807B (sh)
FR (1) FR2678833B1 (sh)
GE (1) GEP19991517B (sh)
GR (2) GR3022355T3 (sh)
HK (1) HK1006207A1 (sh)
HU (1) HU217839B (sh)
IE (2) IE80461B1 (sh)
MX (2) MX9203960A (sh)
NO (2) NO307206B1 (sh)
PL (1) PL169372B1 (sh)
RU (1) RU2134123C1 (sh)
SE (1) SE0593656E5 (sh)
SG (1) SG80541A1 (sh)
SK (1) SK279946B6 (sh)
TW (2) TW495362B (sh)
WO (2) WO1993000929A1 (sh)
YU (1) YU48913B (sh)
ZA (1) ZA924999B (sh)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714512A (en) * 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5750561A (en) * 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
GB2269319B (en) * 1992-08-03 1997-04-09 Bristol Myers Squibb Co Methods for administration of taxol
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
JPH06157330A (ja) * 1992-11-27 1994-06-03 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物，その製造法と用途
US5684169A (en) * 1992-11-27 1997-11-04 Ensuiko Sugar Refining Co., Ltd. Cyclodextrin inclusion complex of taxol, and method for its production and its use
AU5612694A (en) * 1992-11-27 1994-06-22 Napro Biotherapeutics, Inc. Injectable composition
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
ATE339975T1 (de) * 1993-07-19 2006-10-15 Angiotech Pharm Inc Anti-angiogener stent und verfahren zu dessen herstellung
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5686110A (en) * 1994-06-02 1997-11-11 Enzon, Inc. Water soluble complex of an alkyl or olefinic end capped polyalkylene oxide and a water insoluble substance
EP0769936A1 (en) * 1994-07-22 1997-05-02 G.D. Searle & Co. Self-emulsifying drug delivery system
US5681846A (en) * 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
AU724842B2 (en) * 1995-12-21 2000-09-28 Genelabs Technologies, Inc. Taxane composition and method
KR100191446B1 (ko) * 1996-05-02 1999-06-15 송영욱 파클리탁셀 함유 전신성 홍반성 낭창치료제
WO1998053810A1 (en) * 1997-05-30 1998-12-03 Man Woo Han Pharmaceutical injection solution containing taxol
KR100358934B1 (ko) * 1996-09-13 2003-01-29 주식회사한국신약 탁솔을함유한주사용약제조성물
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6638502B1 (en) 1997-04-28 2003-10-28 Gencell Sas Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US20040254635A1 (en) * 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US7208011B2 (en) * 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US7314637B1 (en) 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6388112B1 (en) 1998-10-20 2002-05-14 Ben Venue Laboratories, Inc. Process for purification of solvents useful in the preparation of pharmaceutical compositions
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6290673B1 (en) 1999-05-20 2001-09-18 Conor Medsystems, Inc. Expandable medical device delivery system and method
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
EP2266607A3 (en) 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer
DE60142131D1 (de) 2000-10-16 2010-06-24 Conor Medsystems Inc Expandierbare medizinische Vorrichtung zur Freisetzung eines Heilmittels
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
PL203300B1 (pl) 2000-10-31 2009-09-30 Akad Medyczna Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego
WO2002043765A2 (en) * 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US6964680B2 (en) * 2001-02-05 2005-11-15 Conor Medsystems, Inc. Expandable medical device with tapered hinge
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
KR20020079239A (ko) * 2001-04-14 2002-10-19 이언식 학습기
US7056338B2 (en) * 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US20040249443A1 (en) * 2001-08-20 2004-12-09 Shanley John F. Expandable medical device for treating cardiac arrhythmias
KR100774366B1 (ko) * 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
JP2005515187A (ja) * 2001-11-26 2005-05-26 スーパージェン インコーポレイテッド ポリオキシエチル化ひまし油を使用する医薬組成物の調製方法
US20030101058A1 (en) * 2001-11-26 2003-05-29 Kenneth Liou Voice barcode scan device
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
KR20040088519A (ko) 2002-02-22 2004-10-16 뉴 리버 파마슈티칼스, 인크. 활성 제제 전달 시스템 및 활성 제제의 보호 및 투여 방법
US8313760B2 (en) * 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
NZ575452A (en) * 2002-05-24 2010-03-26 Angiotech Int Ag Compositions and methods for coating medical implants such as vascular grafts, catheters, pacemakers etc
AU2003276920A1 (en) * 2002-09-20 2004-04-08 Innovational Holdings, Llc Expandable medical device with openings for delivery of multiple beneficial agents
US20040127976A1 (en) * 2002-09-20 2004-07-01 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
KR20050105451A (ko) 2003-02-03 2005-11-04 네오팜 인코포레이티드 안정한 멸균 여과가능한 리포좀 캡슐화 탁산 및 다른항종양제
WO2004087214A1 (en) 2003-03-28 2004-10-14 Conor Medsystems, Inc. Implantable medical device with beneficial agent concentration gradient
US7169179B2 (en) * 2003-06-05 2007-01-30 Conor Medsystems, Inc. Drug delivery device and method for bi-directional drug delivery
US7785653B2 (en) * 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
WO2005051444A2 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Soft tissue implants and anti-scarring agents
AU2005100176A4 (en) * 2005-03-01 2005-04-07 Gym Tv Pty Ltd Garbage bin clip
EP1904052A4 (en) * 2005-06-17 2008-12-10 Hospira Australia Pty Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF DOCATEXEL
GB0517092D0 (en) * 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
BRPI0600194A (pt) 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
WO2008026048A2 (en) * 2006-08-31 2008-03-06 Wockhardt Research Centre Stable injectable pharmaceutical compositions of docetaxel
EP1946747A1 (en) * 2007-01-17 2008-07-23 Sandoz AG Pharmaceutical composition of improved stability containing taxane derivatives
CZ200756A3 (cs) * 2007-01-23 2008-07-30 Heaton, A. S. Dvousložková farmaceutická kompozice obsahující taxan
FR2917088B1 (fr) * 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
NZ581589A (en) * 2007-06-22 2012-10-26 Scidose Llc Solubilized sterile injectable formulation of docetaxel without Tween 80
US20090076127A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched larotaxel
FR2922107B1 (fr) 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
ES2344674B1 (es) * 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
EP2204167A1 (en) 2009-01-05 2010-07-07 Azad Pharma AG Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
CN102038635A (zh) 2009-10-23 2011-05-04 天津天士力集团有限公司 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
WO2011139899A2 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
WO2012156999A1 (en) 2011-05-19 2012-11-22 Manu Chaudhary Ready to use docetaxel formulation
LT2753355T (lt) 2011-09-08 2019-01-25 New York University Onkolitinis herpes simplex virusas ir jo terapinis panaudojimas
US9745631B2 (en) 2011-12-20 2017-08-29 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
JP2013194009A (ja) * 2012-03-21 2013-09-30 Nipro Corp ドセタキセル製剤
WO2013177426A2 (en) 2012-05-24 2013-11-28 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
US20150285802A1 (en) 2012-07-18 2015-10-08 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
WO2014013903A1 (ja) 2012-07-19 2014-01-23 富士フイルム株式会社 タキサン系活性成分含有液体組成物、その製造方法及び液体製剤
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
EP2777691A1 (en) * 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
EP2968406A4 (en) 2013-03-14 2016-10-26 Icahn School Med Mount Sinai AUTOLOGOUS TUMOR LYSAT-FILLED DENDRITIC CELL VACCINE FOR THE TREATMENT OF LIVER CANCER
US10130590B2 (en) 2013-10-01 2018-11-20 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
US9493568B2 (en) 2014-03-21 2016-11-15 Abbvie Inc. Anti-EGFR antibodies and antibody drug conjugates
US10350264B2 (en) 2014-03-27 2019-07-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
US10967015B2 (en) 2015-06-15 2021-04-06 New York University Method of treatment using oncolytic viruses
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
EP3468599A2 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-cd98 antibodies and antibody drug conjugates
US20200338209A1 (en) 2016-06-08 2020-10-29 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
EP3468993A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
UA124198C2 (uk) 2016-06-08 2021-08-04 Еббві Інк. Кон'югат антитіла до в7-н3 та лікарського засобу
US20200002432A1 (en) 2016-06-08 2020-01-02 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
JP6292267B2 (ja) * 2016-09-13 2018-03-14 ニプロ株式会社 ドセタキセル製剤
WO2019047812A1 (zh) 2017-09-07 2019-03-14 深圳信立泰药业股份有限公司 多西他赛共缀物的药物组合物及制备方法
JP2018115178A (ja) * 2018-03-15 2018-07-26 ニプロ株式会社 ドセタキセル製剤
WO2020049451A1 (en) 2018-09-05 2020-03-12 Emcure Pharmaceuticals Ltd. Stable ready-to-use carmustine pharmaceutical composition
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206221A (en) * 1979-01-03 1980-06-03 The United States Of America As Represented By The Secretary Of Agriculture Cephalomannine and its use in treating leukemic tumors
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof

Also Published As

Publication number Publication date
FI111808B (fi) 2003-09-30
WO1993000928A1 (fr) 1993-01-21
NO934609L (no) 1993-12-14
IE80548B1 (en) 1998-09-09
DE69217056T3 (de) 2010-04-22
EP0593656B3 (fr) 2009-10-07
EP0593601B1 (fr) 1997-12-17
DE69217056D1 (de) 1997-03-06
EP0522936A1 (fr) 1993-01-13
CZ3294A3 (en) 1995-02-15
NO934609D0 (no) 1993-12-14
AU2278792A (en) 1993-02-11
CA2102777A1 (fr) 1993-01-09
DE69217056T2 (de) 1997-06-05
US5403858A (en) 1995-04-04
HK1006207A1 (en) 1999-02-12
SG80541A1 (en) 2001-05-22
FI940074A0 (fi) 1994-01-07
SE0593656E5 (sv) 2010-11-30
FI940073A0 (fi) 1994-01-07
JP2595458B2 (ja) 1997-04-02
DK0593656T5 (da) 2010-01-11
DE69217056T4 (de) 2009-08-20
EP0593656B1 (fr) 1997-01-22
ATE161193T1 (de) 1998-01-15
EP0522937A1 (fr) 1993-01-13
FI940074A (fi) 1994-01-07
EP0593656A1 (fr) 1994-04-27
FR2678833A1 (fr) 1993-01-15
HU9400052D0 (en) 1994-05-30
SE0593656T3 (sh) 1997-02-03
ES2096091T7 (es) 2010-03-31
GR3025714T3 (en) 1998-03-31
CA2102777C (fr) 2004-09-07
JPH06507913A (ja) 1994-09-08
YU48913B (sh) 2002-11-15
GR3022355T3 (en) 1997-04-30
ZA924999B (en) 1993-04-28
ES2096091T3 (es) 1997-03-01
FI111807B (fi) 2003-09-30
HU217839B (hu) 2000-04-28
HUT65960A (en) 1994-08-29
CZ280965B6 (cs) 1996-05-15
SE0593656T6 (sh) 2010-11-30
RU2134123C1 (ru) 1999-08-10
DE69223624T2 (de) 1998-04-23
IE922212A1 (en) 1993-01-13
WO1993000929A1 (fr) 1993-01-21
MX9203960A (es) 1993-01-01
NO307206B1 (no) 2000-02-28
TW495362B (en) 2002-07-21
IE922213A1 (en) 1993-01-13
FR2678833B1 (fr) 1995-04-07
JPH06507914A (ja) 1994-09-08
KR0136722B1 (ko) 1998-04-25
NO307205B1 (no) 2000-02-28
CA2102778C (fr) 2004-04-20
DE69223624D1 (de) 1998-01-29
CA2102778A1 (fr) 1993-01-09
ES2110003T3 (es) 1998-02-01
FI940073A (fi) 1994-01-07
IE80461B1 (en) 1998-07-29
NO934610D0 (no) 1993-12-14
AU666859B2 (en) 1996-02-29
ATE147992T1 (de) 1997-02-15
DK0593656T3 (da) 1997-02-10
EP0593601A1 (fr) 1994-04-27
MX9203959A (es) 1993-01-01
SK279946B6 (sk) 1999-06-11
NO934610L (no) 1993-12-14
DK0593601T3 (da) 1998-02-09
PL169372B1 (en) 1996-07-31
TW577752B (en) 2004-03-01
GEP19991517B (en) 1999-03-05
SK1594A3 (en) 1994-10-05

Similar Documents

Publication Publication Date Title
YU67692A (sh) Postupak za dobijanje novih smeša na bazi derivata iz klase taksana
MX9400206A (es) Derivados de vinil-azaindol, proceso para su preparacion y composiciones farmaceuticas que los contienen.
HUP0101999A2 (hu) 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
HUP0300434A2 (hu) Oxazolszármazékok és alkalmazásuk tirozin-kináz-inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
MD1233B1 (en) Erythromycin derivatives, process for their preparation and pharmaceutical composition on base thereof
ES2095432T3 (es) Derivados de 2,4-tiazolidin-diona, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
FI921030A0 (fi) Cykliska ureaderivat, dessa foereningar innehaollande laekemedel och foerfarande foer deras framstaellning.
BG106527A (en) Pharmaceutically active sulfonamide derivatives
IL107185A0 (en) 25-Carboxylic acid derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
FR2361901A1 (fr) Derives de substitution de nucleotides et medicament contenant ces substances
NO940523D0 (no) Nye pyrazin-derivater
ES2105362T3 (es) Nuevos derivados de acidos quinolon- y naftiridoncarboxilicos.
YU78092A (sh) Postupak za dobijanje derivata beta-fenilizoserina i njihova primena
ES2176321T3 (es) Derivados tetrasustituidos del imidazol, su procedimiento de preparacion, su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
HUP0003517A2 (hu) Kelátképzők lipofil diészterei, alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
FI834800A0 (fi) Foerfarande foer framstaellning av dialkylaminoalkoxibensylalkohol-derivat
ES2125963T3 (es) Nuevos derivados espiranicos del 3-amino-cromano, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen.
IT1283633B1 (it) Derivati tassanici loro sintesi e formulazioni che li contengono
FI954138A (fi) Hydroksimetyylifuratsaanikarboksyylihappojohdannaiset ja niiden käyttö sydänverisuonitautien käsittelyssä
HUP0300198A2 (hu) Tiokolkicin és bakkatin kondenzációs származékai és ilyen vegyületeket tartalmazó, tumor elleni hatású gyógyászati készítmények
ES2095431T3 (es) N-(isoquinolein-5-il)-sulfonil-azacicloalcanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
YU37594A (sh) Postupak za dobivanje oksazolidinkarboksilne kiseline koja se koristi za dobijanje terapetuski aktivnih taksoida
EE9400143A (et) Bispilokarphappe estri derivaadid, nende valmistamismeetodid ja neid sisaldav farmatseutiline kompositsioon
SE7604030L (sv) Aromatiska alfa-hydroxiamider med insektsavvisande egenskaper
EP0640613A4 (en) OLIGOSIALYL-1,2-DIALKYL-Sn-GLYCEROL AND INTERMEDIATE PRODUCT FOR ITS SYNTHESIS.